Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Goldman Sachs on Microsoft (MSFT): 'Strong cash yields as CapEx growth slows can drive accelerating net interest income'
January 27, 2025 2:11 PM ESTGoldman Sachs analyst Kash Rangan reiterated a Buy rating and $500.00 price target on Microsoft (NASDAQ: MSFT)
The analyst comments "Microsofts -19% TTM vs. NASDAQ despite its pivotal Gen-AI infrastructure cycle and the percolation of Gen-AI into the platform and application layer, coupled with EPS leverage, reaffirms conviction in our Buy rating and $500 PT. While higher COGS, and FX... More
Raymond James Reiterates Strong Buy Rating on Microsoft (MSFT)
January 27, 2025 6:59 AM ESTRaymond James analyst Andrew Marok reiterated a Strong Buy rating and $480.00 price target on Microsoft (NASDAQ: MSFT)
The analyst comments "Microsoft reports F2Q25 results on Wednesday, January 29 after market close. Sentiment still leans positive on Microsoft with AI dominating conversations... More
